Targeted intra-operative radiotherapy

Endomag: New Procedure Spares Women With Breast Cancer From Unnecessary Surgical Complication

Retrieved on: 
Wednesday, December 15, 2021
Oncology, Health, Consumer, Surgery, Women, Biotechnology, Sentinel, Hospital, Hand, LE, Disease, Pain, Swelling, Physician, Radiation, Kakuda, Diagnosis, Learning, Lymph, Incidence, American Journal, Woman, American Journal of Roentgenology, Breast cancer, Cancer, Lymph node, Tail of Spence, Strathcona County, Monroe Dunaway Anderson, Sensation, American College, Motion, Veni, vidi, vici, Trastuzumab, CEO, RN, Therapy, Lymphedema, Quality of life, TAD, MD Anderson Cancer Center, Infection, Lymphatic system, Surgeon, Multimedia, MD, Targeted intra-operative radiotherapy, Treatment, Technology, Heart, Axilla, Dentistry, Cryptocurrency, Medical imaging, Pharmaceutical industry, Silviculture, Endomag, Patient

A novel procedure could now spare breast cancer patients an invasive surgical procedure on their lymphatic system.

Key Points: 
  • A novel procedure could now spare breast cancer patients an invasive surgical procedure on their lymphatic system.
  • Women who win their battle against breast cancer routinely state that lymphedema can be worse than their cancer.
  • This pioneering surgery exemplifies the importance of new technologies such as Magseed in moving breast cancer treatment forward.
  • Prospective Trial of Magnetic Seed Localization of Clipped Nodes after Neoadjuvant Chemotherapy in Node Positive Breast Cancer.

Single-Dose Radiation Therapy for Breast Cancer Removes Treatment Barriers for Underserved Black Women

Retrieved on: 
Thursday, February 18, 2021
Medicine, Clinical medicine, Medical physics, Breast cancer, Radiation therapy, Treatment of cancer, External beam radiotherapy, Cancer, Intraoperative radiation therapy, Targeted intra-operative radiotherapy

The traditional approach to treating stage one or two breast cancer is tumor removal surgery followed by three to six weeks of daily External Beam Radiation Therapy (EBRT).

Key Points: 
  • The traditional approach to treating stage one or two breast cancer is tumor removal surgery followed by three to six weeks of daily External Beam Radiation Therapy (EBRT).
  • The arduous EBRT model is no longer necessary for many early-stage breast cancer cases.
  • However, within both of those income groups, Black women still experienced longer treatment durations than White women.
  • Breast cancer treatment delays by socioeconomic and health care access latent classes in Black and White women, Cancer, September 21, 2020

Intraoperative Radiation Therapy Market worth $66 million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, February 15, 2021
Medicine, Clinical medicine, Health sciences, Medical physics, Intraoperative radiation therapy, Radiation therapy, Brachytherapy, Cancer, Breast cancer, Therapy, Head and neck cancer, Targeted intra-operative radiotherapy

The Electron IORT segment to account for the largest share of the intraoperative radiation therapy market, by technology, in 2019

Key Points: 
  • The Electron IORT segment to account for the largest share of the intraoperative radiation therapy market, by technology, in 2019
    Based on technology, the intraoperative radiation therapy market is segmented into electron IORT and intraoperative brachytherapy.
  • The electron IORT segment is expected to account for the largest share of the market in 2019.
  • Based on application, the intraoperative radiation therapy market is segmented into breast cancer, brain tumor, gastrointestinal cancer, head & neck cancer, colorectal cancer, endometrial and cervical cancer, lung cancer, and other cancers.
  • The Intraoperative radiation therapy products market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Intraoperative Radiation Therapy Market worth $66 million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, February 15, 2021
Medicine, Clinical medicine, Health sciences, Medical physics, Intraoperative radiation therapy, Radiation therapy, Brachytherapy, Cancer, Breast cancer, Therapy, Head and neck cancer, Targeted intra-operative radiotherapy

The Electron IORT segment to account for the largest share of the intraoperative radiation therapy market, by technology, in 2019

Key Points: 
  • The Electron IORT segment to account for the largest share of the intraoperative radiation therapy market, by technology, in 2019
    Based on technology, the intraoperative radiation therapy market is segmented into electron IORT and intraoperative brachytherapy.
  • The electron IORT segment is expected to account for the largest share of the market in 2019.
  • Based on application, the intraoperative radiation therapy market is segmented into breast cancer, brain tumor, gastrointestinal cancer, head & neck cancer, colorectal cancer, endometrial and cervical cancer, lung cancer, and other cancers.
  • The Intraoperative radiation therapy products market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Single-Dose Radiation Therapy Can Counteract Serious Breast Cancer Treatment Compliance Issues During Pandemic

Retrieved on: 
Wednesday, December 16, 2020
Medicine, Clinical medicine, Medical specialties, Intraoperative radiation therapy, Targeted intra-operative radiotherapy, Medical physics, Breast surgery, Lumpectomy, Radiation therapy, Breast cancer, Intraoperative electron radiation therapy, Cancer survival rates

This includes breast cancer, and researchers believe fear of contracting the virus compels patients to stay home instead of completing their post-lumpectomy radiotherapy regimens.

Key Points: 
  • This includes breast cancer, and researchers believe fear of contracting the virus compels patients to stay home instead of completing their post-lumpectomy radiotherapy regimens.
  • IORT is a single treatment which takes the place of external beam radiation therapy (EBRT) done at the time of the lumpectomy.
  • The TARGIT-IORT treatment administers the radiation dose from inside the breast at the time of surgery, precisely where it is needed.
  • The clinical trial demonstrated equal breast cancer recurrence rates and equal cancer survival rates among recipients of targeted IORT during lumpectomy compared to those receiving multiple weeks of whole breast radiation after lumpectomy.

Single-Dose Radiation Therapy At Time Of Lumpectomy Helps Breast Cancer Patients Overcome Treatment Challenges During Pandemic

Retrieved on: 
Wednesday, December 2, 2020
Medicine, Clinical medicine, Medical specialties, Breast cancer, Breast surgery, Surgery, Targeted intra-operative radiotherapy, Intraoperative radiation therapy, Surgical oncology, Breast cancer management, Lumpectomy, Radiation therapy

External beam radiation therapy (EBRT), sometimes referred to as whole breast radiation therapy, involves treating the entire breast from the outside.

Key Points: 
  • External beam radiation therapy (EBRT), sometimes referred to as whole breast radiation therapy, involves treating the entire breast from the outside.
  • 2,298 patients from 32 centers in the UK, USA, Europe, Canada and Australia participated, undergoing lumpectomy for early stage invasive ductal breast cancer.
  • Survival from breast cancer was also similar among those who were allocated risk-adapted targeted IORT during lumpectomy compared to those allocated multiple weeks of whole breast radiation after lumpectomy.
  • With TARGIT-IORT, most patients complete their breast cancer treatment lumpectomy surgery and radiotherapy all at the same time, with lower toxicity.

iCAD Announces Promising Clinical Data to be Presented on Treatment of Early-Stage Breast and Gynecological Cancers at ESTRO 2020 Online Congress

Retrieved on: 
Wednesday, November 25, 2020
Clinical medicine, Medicine, Intraoperative radiation therapy, Radiation therapy, Medical specialties, Breast cancer, Cancer staging, Cancer, Targeted intra-operative radiotherapy, Intraoperative electron radiation therapy

Were thrilled to have new clinical evidence presented at ESTRO 2020 to further demonstrate the value of the Xoft System for the treatment of early-stage breast and gynecological cancers, said Michael Klein, Chairman and CEO of iCAD.

Key Points: 
  • Were thrilled to have new clinical evidence presented at ESTRO 2020 to further demonstrate the value of the Xoft System for the treatment of early-stage breast and gynecological cancers, said Michael Klein, Chairman and CEO of iCAD.
  • Two other posters evaluating Xoft IORT pave the way for future research to fine-tune individual patient treatment plans, continued Klein.
  • These data complement our growing body of research supporting Xofts advanced, multi-platform system for the efficient and targeted treatment of multiple cancer types.
  • Since that time, they have treated more than 600 early-stage breast cancer patients and 150 gynecological cancer patients with the Xoft IORT System.

New Research Presented at Virtual ASTRO Meeting Supports Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological Cancers

Retrieved on: 
Friday, October 23, 2020
Clinical medicine, Medicine, Intraoperative radiation therapy, Radiation therapy, Branches of biology, Cancer staging, Cancer, Breast cancer, Intraoperative electron radiation therapy, Targeted intra-operative radiotherapy

Researchers will present new data supporting the Xoft System for the treatment of early-stage breast cancer and gynecological cancers, as the Company showcases the latest in technology for Xoft including its full suite of applicators for existing and emerging applications in the virtual Xoft exhibition booth.

Key Points: 
  • Researchers will present new data supporting the Xoft System for the treatment of early-stage breast cancer and gynecological cancers, as the Company showcases the latest in technology for Xoft including its full suite of applicators for existing and emerging applications in the virtual Xoft exhibition booth.
  • A growing body of evidence continues to support the Xoft System across multiple cancer types.
  • Researchers concluded that IORT with the Xoft System is safe, with low morbidity, low local recurrence and excellent cosmetic results.
  • The Xoft System remains a leading force in the trend towards more personalized cancer treatment, added Klein.

iCAD’s IORT Excluded from CMS’s Radiation Oncology Alternative Payment Model

Retrieved on: 
Friday, September 18, 2020
Healthcare reform in the United States, Health, Radiation therapy, Federal assistance in the United States, Presidency of Lyndon B. Johnson, Articles, Intraoperative radiation therapy, Bundled payment, Medicaid, Medicare, Therapy, Targeted intra-operative radiotherapy

(NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today provided commentary on the Center for Medicare and Medicaid Services (CMS) Radiation Oncology alternative payment model (RO-APM), which was published today.

Key Points: 
  • (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today provided commentary on the Center for Medicare and Medicaid Services (CMS) Radiation Oncology alternative payment model (RO-APM), which was published today.
  • The new model does not include coverage for iCADs intraoperative radiation therapy (IORT) as part of the new bundled payment system.
  • iCADs IORT will still be covered under its existing CMS reimbursement codes in all geographic markets.
  • The new model provides bundled payments during a 90-day episode of care for 16 different cancer types and is scheduled to take effect on January 1, 2021.

Recently Published Study Shows Effective Treatment for Early-Stage Breast Cancer

Retrieved on: 
Friday, August 28, 2020
Biotechnology, Health, Radiology, Clinical trials, Oncology, Medicine, Medical specialties, Clinical medicine, Targeted intra-operative radiotherapy, Intraoperative radiation therapy, Radiation therapy, Breast cancer, Oncology, Breast cancer management, Intraoperative electron radiation therapy

View the full release here: https://www.businesswire.com/news/home/20200828005309/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200828005309/en/
    Targeted intraoperative radiotherapy demonstrates equivalent long-term outcomes to post-operative whole breast radiotherapy.
  • Every hospital where breast cancer surgery is performed should offer this form of radiation treatment to their breast cancer patients.
  • TARGIT-IORT should be considered the new standard of treatment for early-stage breast cancer based on this large, multi-institutional, prospective, randomized controlled trial.
  • I believe this establishes a new standard for patient-centered, precision oncology and should be offered to all breast cancer patients that meet eligibility requirements.